Logo image of OTLK

OUTLOOK THERAPEUTICS INC (OTLK) Stock Fundamental Analysis

USA - NASDAQ:OTLK - US69012T3059 - Common Stock

1.06 USD
-0.01 (-0.93%)
Last: 10/3/2025, 8:00:02 PM
1.06 USD
0 (0%)
After Hours: 10/3/2025, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, OTLK scores 1 out of 10 in our fundamental rating. OTLK was compared to 536 industry peers in the Biotechnology industry. OTLK has a bad profitability rating. Also its financial health evaluation is rather negative. OTLK is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OTLK had positive earnings in the past year.
In the past year OTLK has reported a negative cash flow from operations.
OTLK had negative earnings in each of the past 5 years.
In the past 5 years OTLK always reported negative operating cash flow.
OTLK Yearly Net Income VS EBIT VS OCF VS FCFOTLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

OTLK has a worse Return On Assets (-194.01%) than 90.49% of its industry peers.
Industry RankSector Rank
ROA -194.01%
ROE N/A
ROIC N/A
ROA(3y)-224.25%
ROA(5y)-230.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTLK Yearly ROA, ROE, ROICOTLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OTLK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTLK Yearly Profit, Operating, Gross MarginsOTLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for OTLK has been increased compared to 1 year ago.
OTLK has more shares outstanding than it did 5 years ago.
OTLK has a better debt/assets ratio than last year.
OTLK Yearly Shares OutstandingOTLK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
OTLK Yearly Total Debt VS Total AssetsOTLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -47.75, we must say that OTLK is in the distress zone and has some risk of bankruptcy.
OTLK's Altman-Z score of -47.75 is on the low side compared to the rest of the industry. OTLK is outperformed by 92.91% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -47.75
ROIC/WACCN/A
WACCN/A
OTLK Yearly LT Debt VS Equity VS FCFOTLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

2.3 Liquidity

OTLK has a Current Ratio of 0.67. This is a bad value and indicates that OTLK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.67, OTLK is not doing good in the industry: 91.79% of the companies in the same industry are doing better.
A Quick Ratio of 0.54 indicates that OTLK may have some problems paying its short term obligations.
OTLK has a Quick ratio of 0.54. This is amonst the worse of the industry: OTLK underperforms 92.35% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.54
OTLK Yearly Current Assets VS Current LiabilitesOTLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

2

3. Growth

3.1 Past

OTLK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 112.68%, which is quite impressive.
EPS 1Y (TTM)112.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OTLK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.61% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.24%
EPS Next 2Y26.06%
EPS Next 3Y29.14%
EPS Next 5Y13.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OTLK Yearly Revenue VS EstimatesOTLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
OTLK Yearly EPS VS EstimatesOTLK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 2.00, the valuation of OTLK can be described as very cheap.
99.44% of the companies in the same industry are more expensive than OTLK, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.86. OTLK is valued rather cheaply when compared to this.
OTLK is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 2
Fwd PE N/A
OTLK Price Earnings VS Forward Price EarningsOTLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTLK Per share dataOTLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
OTLK's earnings are expected to grow with 29.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y26.06%
EPS Next 3Y29.14%

More info and screens

0

5. Dividend

5.1 Amount

OTLK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK (10/3/2025, 8:00:02 PM)

After market: 1.06 0 (0%)

1.06

-0.01 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)12-26 2025-12-26/amc
Inst Owners20.52%
Inst Owner Change-15.7%
Ins Owners0.09%
Ins Owner Change0%
Market Cap47.09M
Analysts80
Price Target8.5 (701.89%)
Short Float %18.95%
Short Ratio1.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.33%
Min EPS beat(2)-37.09%
Max EPS beat(2)34.42%
EPS beat(4)3
Avg EPS beat(4)94.44%
Min EPS beat(4)-37.09%
Max EPS beat(4)191.08%
EPS beat(8)6
Avg EPS beat(8)44.45%
EPS beat(12)8
Avg EPS beat(12)26.17%
EPS beat(16)8
Avg EPS beat(16)12.02%
Revenue beat(2)0
Avg Revenue beat(2)-55.63%
Min Revenue beat(2)-100%
Max Revenue beat(2)-11.26%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.85%
PT rev (3m)-20.64%
EPS NQ rev (1m)13.46%
EPS NQ rev (3m)26.83%
EPS NY rev (1m)1.49%
EPS NY rev (3m)-20.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.59%
Revenue NY rev (1m)22.89%
Revenue NY rev (3m)-0.08%
Valuation
Industry RankSector Rank
PE 2
Fwd PE N/A
P/S 31.28
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.53
EY50%
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0.03
BVpS-0.84
TBVpS-0.84
PEG (NY)0.07
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -194.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-224.25%
ROA(5y)-230.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.54
Altman-Z -47.75
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)112.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.73%
EPS Next Y30.24%
EPS Next 2Y26.06%
EPS Next 3Y29.14%
EPS Next 5Y13.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-38.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.94%
OCF growth 3YN/A
OCF growth 5YN/A